Skip to main content

AutoGenomics and Targeted Molecular Dx to Co-Develop Cancer Biomarker Test on Microarray Platform

NEW YORK, July 28 (GenomeWeb News) - AutoGenomics of Carlsbad, Calif., and Targeted Molecular Diagnostics of Westmont, Ill., will co-develop cancer biomarkers for pharmacogenomic tests on a microarray platform, the companies said yesterday.


Under the three-year partnership, Targeted Molecular will develop BioFilmChip microarray content, based on its knowledge of signaling pathways, while AutoGenomics will develop the tests on its Infiniti platform.


The first test will be a gene expression assay for tumor response and resistance to compounds targeting the HER1 and HER2 pathways. Future assays will cover breast cancer response to therapies, apoptotic response, and resistance to chemotherapy.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.